Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2020
|
| gptkbp:ATCCode |
L01XX72
|
| gptkbp:brand |
gptkb:Zokinvy
|
| gptkbp:CASNumber |
gptkb:193275-84-2
|
| gptkbp:chemicalFormula |
C27H31N5O2
|
| gptkbp:form |
capsule
|
| gptkbp:genericName |
gptkb:lonafarnib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zokinvy
|
| gptkbp:indication |
gptkb:Hutchinson-Gilford_progeria_syndrome
progeroid laminopathies |
| gptkbp:legalStatus |
Rx-only (US)
|
| gptkbp:manufacturer |
gptkb:Eiger_BioPharmaceuticals
|
| gptkbp:mechanismOfAction |
farnesyltransferase inhibitor
|
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea fatigue increased liver enzymes |
| gptkbp:status |
FDA approved
|
| gptkbp:target |
gptkb:farnesyltransferase
|
| gptkbp:bfsParent |
gptkb:lonafarnib
|
| gptkbp:bfsLayer |
7
|